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Abstract
Pertussis or whooping cough remains one of the most poorly controlled vaccine-pre-
ventable diseases across the world. Universal vaccination has dramatically reduced its 
incidence but has failed to bring it completely under control. In the last decades, changes 
in pertussis epidemiology have been noted, likely related to the introduction of acellular 
pertussis vaccines. Increasing incidence is recorded among adolescents and adults who 
have become a reservoir for transmission to unimmunized infants, who are at risk of 
severe disease and death. In Italy, experimental evidences suggest a sustained circulation 
of Bordetella pertussis in the adult population and a significant health burden of pertussis 
among infants less than six months of age. Public health systems are currently exploring 
new vaccination strategies, including a cocooning strategy to prevent the transmission of 
the disease from family members to the newborn and vaccination of pregnant mothers to 
transmit protective antibodies to the offspring, and neonatal vaccination. An integrated 
approach for pertussis control and prevention is needed to enhance the current surveil-
lance system and provide an accurate estimate of the real burden of pertussis in our 
Country, particularly among infants.
Pertussis or whooping cough remains a widespread 
global disease despite the availability of safe and ef-
fective vaccines. Estimates suggest that about 16 mil-
lion new cases of pertussis occurred worldwide in 2008 
and that about 195 000 children died from the disease, 
making pertussis one of the leading cause of vaccine-
preventable death in babies under five years of age [1]. 
The majority of pertussis deaths occur in developing 
countries; however, pertussis not only has persisted, but 
also resurged in countries with high vaccination cover-
age, where epidemic episodes have also been recorded 
[2-4]. Reemergence of pertussis may be attributed to 
various factors including greater awareness of pertussis, 
improved diagnosis due to availability of better labora-
tory tests, genetic changes in circulating Bordetella per-
tussis strains, and increased bacterial circulation among 
adolescents and adults related to the waning of vaccine-
induced immunity [5-7]. In particular, these epide-
miological changes have made adolescents and adults 
a reservoir for B. pertussis and the source of infection 
to the unvaccinated newborns. While adolescents and 
adults tend to have a prolonged illness characterized by 
cough but without other major symptoms, young un-
immunised infants represent the most vulnerable group 
with the highest rates of complications and death. The 
microorganism is generally transmitted through close 
direct contact with an infected person [8] and is highly 
contagious, with up to 90% of household contacts de-
veloping the disease [8].
Acellular pertussis (aP) vaccines containing a varying 
number and quantity of antigens have been licensed 
in several countries in the last decade of the 20th cen-
tury. Efficacy studies have shown an equal ability of 
aP vaccines to protect from the disease as compared 
to old generation whole cell pertussis (wP) vaccines, 
constituted by chemically inactivated whole bacteria 
[9]. However, several years after their introduction, it 
is becoming apparent that immunity conferred by most 
currently used acellular pertussis vaccines wanes more 
rapidly than expected, and vaccinated children are pro-
tected against infections only for a period of 5-8 years 
after their last vaccination [10-12]. Along with waning 
immunity, another emerging drawback of aP vaccines 
is represented by the possibility that, even protecting 
from the disease, they do not prevent colonization and 
transmission, as inferred from studies in non-human 
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primate models of infection and mathematical mod-
eling [13, 14]. In the recent years, extensive research 
efforts allowed to elucidate that natural infection and 
immunization with wP vaccines predominantly in-
duce IFN-γ secreting T-helper (Th) 1 cells and IL-17 
secreting Th17 cells [15-17]. By contrast, it has been 
shown that aP vaccines induce a qualitatively different 
immune response, characterized by the induction of 
Th2 immunity [13, 15, 18]. It is conceivable that this 
difference, along with the chemical inactivation of the 
pertussis toxin antigen in aP vaccines, may account for 
either lack of protection of vaccines from colonization 
and suboptimal T-cell priming with reduced efficiency 
in the generation of a immune memory repertoire.
The apparent changing epidemiology of pertussis 
calls for enhanced disease surveillance. The evalua-
tion of pertussis incidence is a complex task, and sev-
eral hurdles hamper a precise estimate of the pertussis 
disease burden. Limited surveillance infrastructures, 
unavailability of appropriate diagnostic tests and clini-
cal underdiagnosis of the disease may hinder case re-
porting. In Italy, pertussis is a notifiable disease but the 
diagnosis of pertussis still relies on clinical symptoms 
and microbiological confirmation is rarely performed 
in the country [19, 20]. Underreporting has a signifi-
cant impact with regard to older children, adolescents, 
and adults, for whom the cough pattern may be atypi-
cal [21]. A recent study on the seroprevalence of anti-
pertussis toxin IgG among adult age groups in Italy has 
shown that B. pertussis is circulating widely in the Italian 
population [22]. These findings confirm previous data 
[23] and suggest that pertussis is resurging or, at least, 
still circulates in Italy. 
Pediatric populations, too young to be protected by 
vaccination, experience much more severe disease than 
children and adults. Data from the Italian Ministry of 
Health report that, after the introduction of acellular 
vaccines, infants less than 1 year of age continue to be 
the age group with the highest incidence rates [24]. A 
retrospective study reviewing the Italian national hos-
pital discharge form database showed that, in the pe-
riod 1999-2009, most hospitalizations (57.4%) involved 
subjects < 1 year of age [25]. Recently, a dramatic re-
surgence of pertussis has been registered in Tuscan in-
fants [26]. As stated before, the combination of waning 
vaccine immunity and increased B. pertussis circulation 
among adults may detrimentally contribute to the trans-
mission of the bacteria to young infants. In this regard, 
it has been recently shown that parents were the main 
source for pertussis transmission to infants hospitalized 
in two big pediatric hospitals in Rome [27].
It is worth noting that the clinical diagnosis of pertus-
sis is not easy in early infancy, since clinical manifesta-
tions can overlap with several other respiratory infec-
tions. Nevertheless, symptoms as paroxysmal cough, 
apnea, cyanosis, are very often associated with pertussis 
in babies. In school-age children, the majority of whom 
have been vaccinated, the disease is less severe, and 
they are more likely to display the typical symptoms of 
pertussis, including coughing spasms followed by the in-
spiratory “whoop” and vomiting [21]. Adolescents and 
adults may present cough and cold-like symptoms, but 
without whooping or vomiting. In a minority of adult, 
pertussis leads to complications such as seizures, pneu-
monia, and otitis media [28]. Due to different clinical 
presentations among infants, adolescents, and adults, 
a differential lab-confirmation diagnosis is required, in 
order to update the epidemiological situation. More-
over, the molecular characterization of the circulating 
strains may contribute to identify those harboring vari-
ant strains for one or more vaccine antigens possibly 
due to vaccine pressure.
The resurgence of pertussis as a public health con-
cern, changes in the epidemiology of the disease, and 
the increasing attitude of parents in delaying or miss-
ing vaccination for their children, highlight the urgent 
need for integrated approaches to prevent this poten-
tially deadly childhood disease. New vaccination strate-
gies have been experimented, such as the “cocooning 
strategy” and maternal immunization. Cocooning re-
fers to the vaccination of mothers and other contacts 
of newborns and infants. Cost-effective cocooning is 
difficult to implement since a successful programme 
implies very high numbers of contacts to be vaccinated 
in order to reach a significant impact on severe infant 
pertussis [29]. Currently, there is a growing evidence 
for effectiveness of immunization of women during 
pregnancy, rather than during the immediate postpar-
tum period. This approach has been found to be more 
cost- effective, and vaccine effectiveness against infant 
deaths was estimated at 95% [30]. Alongside the vac-
cination of contacts, an alternative option that could 
be considered is an early infant vaccination schedule at 
6-8 weeks of age. However, even with an accelerated 
antibody response, infants would remain unprotected 
during the most vulnerable time window for severe and 
life-threatening pertussis. 
In conjunction with novel immunization approaches, 
improved pertussis surveillance is required for the con-
trol of infant pertussis. Evaluation of vaccine efficacy 
may help to improve the understanding of how well and 
how long pertussis vaccines protect in the field. Thus, 
a targeted surveillance, understanding the epidemiol-
ogy of the disease, might contribute to better define the 
burden of disease and facilitate the adaptation of vac-
cine strategies. At the same time,  monitoring the evolu-
tion of the bacteria might allow the timely detection of 
escape mutants, particularly the emergence of strains 
not expressing the vaccine antigen pertactin [31, 32].
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